Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Pragmatic Adaptive Randomized, Controlled Phase II/III Multicenter Study of IFX-1 in Patients With Severe COVID-19 Pneumonia

NCT04333420 is registered in ClinicalTrials.gov with InflaRx GmbH as lead sponsor.

NCT NCT04333420
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04333420 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Pragmatic Adaptive Randomized, Controlled Phase II/III Multicenter Study of IFX-1 in Patients With Severe COVID-19 Pneumonia
Lead sponsor
InflaRx GmbH
Phase
Phase 2/3
Overall status
Completed
Start date
March 31, 2020
Completion date
December 1, 2021
Enrollment
399 (actual)
Sites
48

Conditions

As the registry lists them; a condition with its own page is linked.

severe covid-19 pneumonia